Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astagraf XL versus immediate-release tacrolimus for prevention of de novo donor-specific antibodies and immune activation after kidney transplantation
2018-003867-79Phase 4
- Sponsor
- Astellas Pharma
- Start
- Nov 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in kidney allograft rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Combined incidence of de novo donor-specific antibodies or immune activation.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2018-003867-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003867-79.